Supporting information for

## Onydecalins, Fungal Polyketides with Anti-Histoplasma and Anti-TRP Activity

Zhenjian Lin,<sup>†</sup> Sujal Phadke,<sup>‡</sup> Zhenyu Lu,<sup>§</sup> Sinem Beyhan,<sup>‡</sup> May H. Abdel Aziz,<sup>§</sup> Chris Reilly, <sup>§</sup> Eric W. Schmidt<sup>\*,†</sup>

<sup>†</sup>Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112

<sup>\*</sup>Department of Infectious Diseases, J. Craig Venter Institute, La Jolla, CA 92037

<sup>§</sup>Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT 84112

## List of the supporting information.

- Figure S1. <sup>1</sup>H NMR spectrum of compound **1** in DMSO-*d*<sub>6</sub>.
- Figure S2. HSQC of compound 1 in DMSO-*d*<sub>6</sub>.
- Figure S3. HMBC of compound 1 in DMSO-d<sub>6</sub>.
- Figure S4.  $^{1}$ H- $^{1}$ H COSY of compound 1 in DMSO- $d_{6}$ .
- Figure S5. ROESY of compound 1 in DMSO- $d_6$ .
- Figure S6. <sup>1</sup>H NMR of TFA salt of compound 1 in DMSO- $d_6$ .
- Figure S7. <sup>13</sup>C NMR of TFA salt of compound 1 in DMSO-*d*<sub>6</sub>.
- Figure S8. HSQC of TFA salt of compound 1 in DMSO- $d_6$ .
- Figure S9. HMBC of TFA salt of compound 1 in DMSO-*d*<sub>6</sub>.
- Figure S10. COSY of TFA salt of compound 1 in DMSO-d<sub>6</sub>.
- Figure S11. <sup>1</sup>H NMR of compound **2** in DMSO-*d*<sub>6</sub>.
- Figure S12. <sup>13</sup>C NMR of compound **2** in DMSO-*d*<sub>6</sub>.
- Figure S13. HSQC of compound 2 in DMSO-*d*<sub>6</sub>.
- Figure S14. <sup>1</sup>H-<sup>1</sup>H COSY of compound **2** in DMSO-*d*<sub>6</sub>.
- Figure S15. ROESY of compound 2 in DMSO-d<sub>6</sub>.
- Figure S16. <sup>1</sup>H NMR of compound **3** in CDCl<sub>3</sub>.
- Figure S17. <sup>13</sup>C NMR of compound **3** in CDCl<sub>3</sub>.
- Figure S18. HSQC of compound 3 in CDCl<sub>3</sub>.
- Figure S19. HMBC of compound 3 in CDCl<sub>3</sub>.

- Figure S20. <sup>1</sup>H-<sup>1</sup>H COSY of compound **3** in CDCl<sub>3</sub>.
- Figure S21. NOESY of compound 3 in CDCl<sub>3</sub>.
- Figure S22. <sup>1</sup>H NMR of compound 4 in CDCl<sub>3</sub>.
- Figure S23. <sup>13</sup>C NMR of compound 4 in CDCl<sub>3</sub>.
- Figure S24. HSQC of compound 4 in CDCl<sub>3</sub>.
- Figure S25. HMBC of compound 4 in CDCl<sub>3</sub>.
- Figure S26. <sup>1</sup>H-<sup>1</sup>H COSY of compound 4 in CDCl<sub>3</sub>.
- Figure S27. NOESY of compound 4 in CDCl<sub>3</sub>.
- Figure S28. ADEQUATE spectrum of <sup>13</sup>C labeled compound 1 in DMSO-*d*<sub>6</sub>.
- Figure S29. The <sup>1</sup>H NMR of <sup>13</sup>C labeled and natural compound **1**.
- Figure S30. The <sup>13</sup>C NMR of <sup>13</sup>C labeled and natural compound **1**.
- Figure S31. CD spectrum of compound 1
- Figure S32. CD spectrum of compound 2
- Figure S33. CD spectrum of compound 3
- Figure S34. CD spectrum of compound 4
- Figure S35. Dose response of TRPV channel inhibition.
- Figure S36. Effects of onydecalins on *H. capsulatum* growth.
- Figure S37. Effects of onydecalins on fungal growth

Table S1. Antagonist activity of compounds 1-4 against a panel of TRP channel.

Scheme S1. Proposed biogenesis of compound 1-4. Red: <sup>13</sup>C-<sup>13</sup>C coupled carbons resulting from feeding with U-<sup>13</sup>C-glucose. Squares: <sup>13</sup>C-enriched carbons resulting from feeding with U-<sup>13</sup>C-glucose.

Figure S1. <sup>1</sup>H NMR spectrum of compound **1** in DMSO-*d*<sub>6</sub>.



Figure S3. HMBC of compound 1 in DMSO-*d*<sub>6</sub>.



Figure S4. <sup>1</sup>H-<sup>1</sup>H COSY of compound 1 in DMSO- $d_6$ .



Figure S5. ROESY of compound 1 in DMSO-d<sub>6</sub>.



Figure S6. <sup>1</sup>H NMR of TFA salt of compound 1 in DMSO- $d_6$ .





Figure S7. <sup>13</sup>C NMR of TFA salt of compound **1** in DMSO-*d*<sub>6</sub>.

Figure S8. HSQC of TFA salt of compound 1 in DMSO-d<sub>6</sub>.





Figure S9. HMBC of TFA salt of compound 1 in DMSO-*d*<sub>6</sub>.

Figure S10. COSY of TFA salt of compound 1 in DMSO-d<sub>6</sub>.



Figure S11. <sup>1</sup>H NMR of compound **2** in DMSO- $d_6$ .



Figure S13. HSQC of compound **2** in DMSO-*d*<sub>6</sub>.



Figure S14. <sup>1</sup>H-<sup>1</sup>H COSY of compound **2** in DMSO- $d_6$ .



Figure S15. ROESY of compound **2** in DMSO-*d*<sub>6</sub>.



Figure S16. <sup>1</sup>H NMR of compound **3** in CDCl<sub>3</sub>.





Figure S17. <sup>13</sup>C NMR of compound **3** in CDCl<sub>3</sub>.

Figure S18. HSQC of compound 3 in CDCl<sub>3</sub>.



Figure S19. HMBC of compound 3 in CDCl<sub>3</sub>.



Figure S20. <sup>1</sup>H-<sup>1</sup>H COSY of compound **3** in CDCl<sub>3</sub>.



Figure S21. NOESY of compound 3 in CDCl<sub>3</sub>.



2.0 11.0 10.0 9.0 8.0 7.0 6.0 5.0 4.0 3.0 2.0 1.0 f1 (ppm)

0.0

Figure S23. <sup>13</sup>C NMR of compound **4** in CDCl<sub>3</sub>.



Figure S25. HMBC of compound 4 in CDCl<sub>3</sub>.



Figure S26. <sup>1</sup>H-<sup>1</sup>H COSY of compound 4 in CDCl<sub>3</sub>.



Figure S27. NOESY of compound 4 in CDCl<sub>3</sub>.



Figure S28. ADEQUATE spectrum of  $^{13}$ C labeled compound 1.



Figure S29. The <sup>1</sup>H NMR of <sup>13</sup>C labeled and natural compound **1**.



Figure S30. The <sup>13</sup>C NMR of <sup>13</sup>C labeled and natural compound **1**.







Figure S32. CD spectrum of compound 2







Figure S34. CD spectrum of compound 4





Figure S35. Dose response of TRPV channel inhibition.

Figure S36. Effects of onydecalins on *H. capsulatum* growth. Itraconazole, amphotericin B, and compounds **3** and **4** were tested for their antifungal properties against *H. capsulatum* at a series of concentrations. Plates were incubated at 37 °C with 5% CO<sub>2</sub> for 10-14 days. The images shown were from the wells containing each compound at the indicated concentration ( $\mu$ g/ml). These experiments were repeated at least three independent times and representative images are shown.



Figure S37. Effects of onydecalins on fungal growth. Four compounds were tested for their anti-fungal properties at a series of concentrations (0.25 to 64  $\mu$ g/ml) against *A. fumigatus* and *C. albicans*. The plates containing *C. albicans* and *A. fumigatus* were incubated for 48 hours at 30 °C and 37 °C, respectively. None of the compounds inhibited the growth of *A. fumigatus* and *C. albicans* at any of the ten concentrations tested. The images shown were from the wells containing the highest (64  $\mu$ g/ml) concentration of the respective compound. These experiments were repeated at least three independent times.



Table S1. Antagonist activity of compounds 1-4 against a panel of TRP channel subtypes (IC<sub>50</sub> values in

μM\*).

compound	TRPA1	TRPM8	TRPV1	TRPV3	TRPV4
1	> 100	> 100	81.6	> 100	45.9
2	> 100	18.5	> 100	> 100	> 100
3	NT	> 100	NT	> 100	> 100
4	NT	61.6	NT	NT	> 100
capsazepine			0.5		
HC-067047					0.024
AMTB		5			

NT=not tested



Scheme S1. Proposed biogenesis of compound 1-4. Red: <sup>13</sup>C-<sup>13</sup>C coupled carbons resulting from feeding with U-<sup>13</sup>C-glucose. Squares: <sup>13</sup>C-enriched carbons resulting from feeding with U-<sup>13</sup>C-glucose.